Pediatric Obesity and GLP-1: The SCALE Teens Trial and Ethical Considerations

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

GLP-1 receptor agonists, as evidenced by trials like SCALE Teens, are effective for pediatric obesity but raise ethical considerations regarding long-term use, access, and potential psychological impacts on adolescents.

Pediatric obesity has reached epidemic proportions globally, posing significant immediate and long-term health risks, including type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, and psychosocial issues. Lifestyle interventions remain the cornerstone of treatment, but for many adolescents with severe obesity, these are insufficient. The emergence of highly effective pharmacotherapies, particularly glucagon-like peptide-1 (GLP-1) receptor agonists, offers new hope but also introduces complex ethical considerations unique to the pediatric population. The SCALE Teens trial, investigating liraglutide, and more recently, trials for semaglutide, have provided crucial data in this evolving landscape.

The SCALE Teens Trial: Efficacy of Liraglutide

The SCALE Teens trial was a phase 3, randomized, double-blind, placebo-controlled trial that evaluated the efficacy and safety of liraglutide 3.0 mg (or maximum tolerated dose) once daily, as an adjunct to lifestyle therapy, for weight management in adolescents aged 12 to <18 years with obesity [1].

Key findings from the SCALE Teens trial included:

Significant Weight Reduction: After 56 weeks, adolescents treated with liraglutide achieved a mean reduction in BMI standard deviation score (SDS) of -0.22, compared to an increase of 0.06 in the placebo group. The mean percentage change in BMI was -2.69% with liraglutide versus +0.46% with placebo [1].

Clinical Response: A greater proportion of adolescents in the liraglutide group achieved a ≥5% reduction in BMI (26.1% vs. 8.1% with placebo) and ≥10% reduction (9.7% vs. 2.6% with placebo) [1].

Safety Profile: The safety profile was generally consistent with that observed in adults, with gastrointestinal adverse events (nausea, vomiting, diarrhea) being the most common. There was a higher incidence of cholelithiasis in the liraglutide group (1.5% vs. 0% with placebo) [1].

More recently, semaglutide 2.4 mg once weekly has also demonstrated superior efficacy in adolescents with obesity, showing a mean reduction in BMI of 16.1% compared to 0.6% with placebo in a 68-week trial, further solidifying the role of GLP-1 RAs in this population [2].

Ethical Considerations in Pediatric GLP-1 RA Use

The use of powerful weight-loss medications in adolescents raises several important ethical considerations that clinicians, parents, and patients must navigate:

  • Long-Term Safety and Efficacy: While short-to-medium term data are promising, the long-term effects of GLP-1 RAs on growth, bone health, and overall development in adolescents are still being studied. The duration of treatment and potential for lifelong medication use need careful consideration [3].
  • Impact on Body Image and Mental Health: While weight loss can improve self-esteem, the emphasis on pharmacotherapy for weight can also inadvertently reinforce societal pressures around body image. It is crucial to integrate psychological support to address body dissatisfaction, disordered eating patterns, and mental health comorbidities common in adolescents with obesity [4].
  • Autonomy and Assent: Adolescents, particularly older ones, should be involved in shared decision-making regarding their treatment. Their understanding of the medication, potential side effects, and long-term implications must be assessed, and their assent obtained, even if parental consent is legally required [5].
  • Access and Equity: The high cost of GLP-1 RAs can create disparities in access, potentially exacerbating health inequities. Ensuring equitable access to these effective treatments, alongside comprehensive lifestyle support, is an ethical imperative.
  • Medicalization of Obesity: While obesity is a disease, relying solely on pharmacological solutions without addressing underlying lifestyle, environmental, and social determinants can be problematic. A holistic approach that integrates medication with robust behavioral and family-based interventions is essential.
  • Off-Label Use: While liraglutide 3.0 mg is approved for adolescents aged 12 and older, other GLP-1 RAs may be used off-label, which requires careful discussion with families about the evidence and risks.

    • Practical Takeaways for Clinicians

    Comprehensive Assessment: Conduct a thorough medical and psychosocial evaluation before considering GLP-1 RAs.

    Multidisciplinary Approach: Integrate pharmacotherapy with intensive lifestyle interventions, nutritional counseling, and psychological support.

    Shared Decision-Making: Engage adolescents and their families in open discussions about treatment goals, expectations, risks, and benefits.

    Monitor Closely: Monitor for both physical side effects (especially GI and gallbladder issues) and psychological well-being.

    Advocate for Access: Work to ensure that effective treatments are accessible to all eligible adolescents, regardless of socioeconomic status.

    Conclusion

    The SCALE Teens trial and subsequent studies have firmly established GLP-1 RAs as effective tools in the management of pediatric obesity. However, their use in this vulnerable population demands a nuanced approach that extends beyond efficacy and safety data. Addressing the ethical considerations surrounding long-term use, psychological impact, patient autonomy, and equitable access is crucial to ensure that these powerful medications are utilized responsibly and beneficially for adolescents struggling with obesity.